公开(公告)号：US11472809B2

公开(公告)日：2022-10-18

申请号：US17014533

申请日：2020-09-08

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Alpay Dermenci ,  Andrew Fensome ,  Brian Stephen Gerstenberger ,  Matthew Merrill Hayward ,  Dafydd Rhys Owen ,  Stephen Wayne Wright ,  Li Huang Xing ,  Xiaojing Yang

IPC: A61K31/4985 ,  C07D487/04

Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

公开(公告)号：US20220323558A1

公开(公告)日：2022-10-13

申请号：US17319395

申请日：2021-05-13

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  A61K48/00

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US20220306641A1

公开(公告)日：2022-09-29

申请号：US17693197

申请日：2022-03-11

Applicant: PFIZER INC.

Inventor： Ketan Satish GAJIWALA ,  Chan Woo HUH ,  Mehran JALAIE ,  Ryan Lloyd PATMAN ,  Eugene Yuanjin RUI ,  Jianmin SUN ,  Martin James WYTHES

IPC: C07D487/04 ,  C07D471/04

Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

公开(公告)号：US11452711B2

公开(公告)日：2022-09-27

申请号：US17660270

申请日：2022-04-22

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Qingyi Yang

IPC: C07D403/12 ,  A61K31/403 ,  A61P31/14 ,  A61K31/427 ,  A61K31/401

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20220251066A1

公开(公告)日：2022-08-11

申请号：US17458862

申请日：2021-08-27

Applicant: Pfizer Inc.

Inventor： Michael Joseph Luzzio ,  Kevin Daniel Freeman-Cook ,  Samit Kumar Bhattacharya ,  Matthew Merrill Hayward ,  Catherine Angela Hulford ,  Christopher Lowell Autry ,  Xumiao Zhao ,  Jun Xiao ,  Kendra Louise Nelson

IPC: C07D401/12 ,  C07D239/48 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D241/20 ,  C07D475/00

Abstract: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

公开(公告)号：US20220235141A1

公开(公告)日：2022-07-28

申请号：US17613304

申请日：2020-05-21

Applicant: Pfizer Inc.

Inventor： Stephen George Dann ,  Cecilia Marianne Oderup ,  Shahram Salek-Ardakani

IPC: C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  A61P35/00

Abstract: This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.

公开(公告)号：US20220227874A1

公开(公告)日：2022-07-21

申请号：US17586321

申请日：2022-01-27

Applicant: Pfizer Inc.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: C07K16/28 ,  C07K14/47 ,  C07K14/725

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US11365253B2

公开(公告)日：2022-06-21

申请号：US16614701

申请日：2018-06-08

Applicant: Pfizer Inc. ,  Boston Medical Center Corporation

Inventor： Stephen Berasi ,  Janet Elizabeth Buhlmann ,  Eric M. Bennett ,  Nathan Higginson-Scott ,  Huilan Gao ,  Zong Sean Juo ,  Stefano V. Gulla ,  Christine Huard ,  Sreekumar R. Kodangattil ,  Jian Li ,  Weining Lu ,  Xueping Fan ,  David J. Salant

IPC: C07H21/04 ,  C12P21/06 ,  C12N15/87 ,  C12N1/20 ,  C12N15/74 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  A61P13/12 ,  C12N15/85

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.

公开(公告)号：US20220184199A1

公开(公告)日：2022-06-16

申请号：US17601949

申请日：2020-04-06

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Isis Kanevsky ,  Farid Latif Khan ,  Charles Harold Jones ,  John Michael McLaughlin

IPC: A61K39/09

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US20220184041A1

公开(公告)日：2022-06-16

申请号：US17533592

申请日：2021-11-23

Applicant: Pfizer Inc.

Inventor： Shawn Cabral ,  Daniel Paul Canterbury ,  Robert Lee Dow ,  Andrew Fensome ,  Magdalena Korczynska ,  Sophie Yvette Lavergne ,  Allyn Timothy Londregan ,  Vincent Mascitti ,  David Walter Piotrowski ,  Andre Shavnya ,  Meihua Mike Tu ,  Tao Wang ,  Hanna Maria Wisniewska

IPC: A61K31/428 ,  C07D417/04 ,  C07D513/04 ,  A61K31/437 ,  A61K31/353 ,  A61K31/423 ,  A61K31/415 ,  A61K31/192 ,  A61K31/12 ,  A61K31/7105

Abstract: This application includes a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein the variables R1a, R1b, R2, R3, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.